Zacks Research Has Negative Forecast for AGIO Q3 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities research analysts at Zacks Research lowered their Q3 2025 earnings estimates for Agios Pharmaceuticals in a report released on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($1.80) for the quarter, down from their previous estimate of ($1.79). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($4.87) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.79) EPS, FY2025 earnings at ($6.99) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.57) EPS, Q3 2026 earnings at ($1.52) EPS and FY2026 earnings at ($5.95) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. During the same period last year, the business earned ($1.51) EPS. The firm’s revenue was up 28.4% compared to the same quarter last year.

Several other analysts have also weighed in on the stock. Scotiabank began coverage on shares of Agios Pharmaceuticals in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $51.00 target price for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. Raymond James reaffirmed an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Finally, Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $52.00.

Agios Pharmaceuticals Trading Up 1.7 %

AGIO stock opened at $45.08 on Friday. Agios Pharmaceuticals has a twelve month low of $19.80 and a twelve month high of $53.28. The company has a market capitalization of $2.56 billion, a P/E ratio of -7.13 and a beta of 0.75. The firm has a 50 day simple moving average of $44.64 and a 200-day simple moving average of $41.46.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Caxton Associates LP boosted its holdings in shares of Agios Pharmaceuticals by 0.7% in the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock worth $1,615,000 after acquiring an additional 264 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Agios Pharmaceuticals by 0.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 314 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Agios Pharmaceuticals by 1.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock worth $911,000 after acquiring an additional 540 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $37,000. Finally, Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $40,000.

Insider Activity at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.